Company intelligence
AtriCure, Inc.
We are passionately focused on healing the lives of those affected by Afib and pain after surgery.
About AtriCure, Inc.
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide. Electrophysiologists, cardiothoracic and thoracic surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications and post-operative pain management. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE®+ and cryoSPHERE MAX™ probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on X (formerly Twitter) @AtriCure.
Verified activity
Signals from AtriCure, Inc.
22 published signals
Presence & Recognition
AtriCure, Inc. treated 800,000 patients with the AtriClip, shaping the future of LAA exclusion
Reported by AtriCure, Inc.
Presence & Recognition
AtriCure, Inc. is featured in two presentations at the upcoming ECTSS Meeting exploring advancements in intercostal cryoablation.
Reported by AtriCure, Inc.
Research & Knowledge
AtriCure, Inc. presented new data at the ESC2026 meeting led by Associate Prof. Dr. Riyaz Kaba, demonstrating significantly greater freedom from atrial arrhythmias after hybrid epicardial-endocardial ablation compared to catheter ablation alone in patients with persistent and long-standing persistent Afib and reduced left ventricular ejection fraction.
Reported by AtriCure, Inc.